Latest Content

The FDA approved Tregzi, a precision-engineered cell therapy, to improve chronic GVHD-free survival in adults undergoing allogeneic transplant.

PROSPER data reveal that mogamulizumab provides rapid, sustained relief from skin symptoms and improves sleep for patients with MF and SS.

The FDA approved Azurity’s Aprepitant Injectable Emulsion, a polysorbate-80-free, ready-to-use IV option for preventing chemotherapy-induced nausea.

New research finds younger generations age faster biologically, increasing risks for early-onset lung, colorectal, and other solid tumor cancers.

Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates.

The FDA approved the BESREMi Pen for polycythemia vera, offering a simplified self-administration option to improve patient adherence and care.

Rita M. Jakubowski, NP, explains how multidisciplinary age-friendly assessments and the CHARM study improve outcomes for older transplant patients.

Dr. Sonja J. Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and survivors.

Diane Stanaway, MSN, RN, highlights the importance of long-term skin protection for oncology patients during high-exposure events like the World Cup.

FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer.

The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial.

Dr. Sriram Machineni explains why GLP-1 medications help manage cardiovascular health and inflammation in breast cancer survivorship.

Christina Klawitter explores the evolving role of oncology research nurses, highlighting the importance of pre-planning and interdisciplinary teamwork.